Mohamed Wa’el Ahmed Hashad
Chief Executive Officer bei LONGEVERON INC.
Vermögen: 63 752 $ am 31.03.2024
Profil
Mohamed Wa’el Ahmed Hashad is currently the Chief Executive Officer & Director at Longeveron, Inc., an Independent Director at Akari Therapeutics Plc, and a Director at California Life Sciences Association.
Previously, he served as the President & Chief Executive Officer at Avanir Pharmaceuticals, Inc. from 2020 to 2023 and as the Chief Commercial Officer & Executive VP at Seres Therapeutics, Inc. from 2016 to 2017.
He holds an undergraduate degree from the University of Pennsylvania, an MBA from the University of Akron, and another undergraduate degree from the University of Cairo.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
LONGEVERON INC. CLASS A
1,91% | 11.04.2024 | 19 616 ( 1,91% ) | 63 752 $ | 31.03.2024 |
Aktive Positionen von Mohamed Wa’el Ahmed Hashad
| Unternehmen | Position | Beginn |
|---|---|---|
| LONGEVERON INC. | Chief Executive Officer | 01.03.2023 |
| AKARI THERAPEUTICS, PLC | Director/Board Member | 05.07.2023 |
California Life Sciences Association
 California Life Sciences Association Miscellaneous Commercial ServicesCommercial Services California Life Sciences Association (CLSA) is the largest and most influential life sciences advocacy and business leadership organization in California. The non-profit company is based in South San Francisco, CA, and has offices in other locations as well. The company works closely with industry, government, academia, and others to shape public policy, improve access to innovative technologies, and grow California's life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device, and diagnostics companies, research universities and institutes, investors, and service providers throughout the state. Mike Guerra has been the CEO of the company since 2019. | Director/Board Member | - |
Ehemalige bekannte Positionen von Mohamed Wa’el Ahmed Hashad
| Unternehmen | Position | Ende |
|---|---|---|
| AVANIR PHARMACEUTICALS INC | Chief Executive Officer | 01.01.2023 |
| SERES THERAPEUTICS, INC. | Corporate Officer/Principal | 21.06.2017 |
Ausbildung von Mohamed Wa’el Ahmed Hashad
| University of Pennsylvania | Undergraduate Degree |
| University of Akron | Masters Business Admin |
| University of Cairo | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| SERES THERAPEUTICS, INC. | Health Technology |
| AKARI THERAPEUTICS, PLC | Health Technology |
| LONGEVERON INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Avanir Pharmaceuticals, Inc.
 Avanir Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Avanir Pharmaceuticals, Inc. engages in the development of therapeutic products for the treatment of nervous system disorder. The company was founded on August 31, 1988 and headquartered in Aliso Viejo, CA. | Health Technology |
California Life Sciences Association
California Life Sciences Association Miscellaneous Commercial ServicesCommercial Services California Life Sciences Association (CLSA) is the largest and most influential life sciences advocacy and business leadership organization in California. The non-profit company is based in South San Francisco, CA, and has offices in other locations as well. The company works closely with industry, government, academia, and others to shape public policy, improve access to innovative technologies, and grow California's life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device, and diagnostics companies, research universities and institutes, investors, and service providers throughout the state. Mike Guerra has been the CEO of the company since 2019. | Commercial Services |
